
Neuro Event Labs is a Finnish digital health technology company founded in 2015, focused on improving the lives of epilepsy patients through innovative software-driven solutions. Their flagship product, Nelli®, is a CE-marked medical device that utilizes AI for accurate seizure detection and monitoring, providing critical data to healthcare professionals. With adoption in over 30 hospitals and recognition from regulatory bodies, Neuro Event Labs aims to set a new standard in epilepsy diagnostics and monitoring, enhancing patient care and outcomes.

Neuro Event Labs is a Finnish digital health technology company founded in 2015, focused on improving the lives of epilepsy patients through innovative software-driven solutions. Their flagship product, Nelli®, is a CE-marked medical device that utilizes AI for accurate seizure detection and monitoring, providing critical data to healthcare professionals. With adoption in over 30 hospitals and recognition from regulatory bodies, Neuro Event Labs aims to set a new standard in epilepsy diagnostics and monitoring, enhancing patient care and outcomes.
Founded: 2015 in Tampere, Finland
Headcount: 34 employees
Flagship product: Nelli® — AI video & audio seizure detection and monitoring
Regulatory status: FDA Breakthrough Device designation (2020); EU MDR Class IIa (Dec 20, 2024)
Adoption: Used in 30+ hospitals
Total funding (reported): USD 7,390,000
Epilepsy diagnosis and monitoring
2015
Digital health / Medtech
Early investment reported in March 2018; reported contributions included public support (Business Finland).
Grant funding recorded March 20, 2020.
EUR 3.9M
Series A announced April 8–9, 2020 with participation from Hadean Ventures, SHS Capital and Maki.vc.
Convertible note round recorded July 10, 2023.
EUR 2.0M
Financing announced Feb 12, 2025 with participation from Hadean Ventures and others to support commercial expansion.
“Has backing from specialized health/venture investors (Hadean Ventures, SHS Capital, Maki.vc) and public innovation grants; recent participation from Catalyze Capital.”